Dataset Information


Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C?>?T) mutation in ?-thalassemia-derived iPSCs.

ABSTRACT: ?-Thalassemia is one of the most common genetic blood diseases and is caused by either point mutations or deletions in the ?-globin (HBB) gene. The generation of patient-specific induced pluripotent stem cells (iPSCs) and subsequent correction of the disease-causing mutations may be a potential therapeutic strategy for this disease. Due to the low efficiency of typical homologous recombination, endonucleases, including TALENs and CRISPR/Cas9, have been widely used to enhance the gene correction efficiency in patient-derived iPSCs. Here, we designed TALENs and CRISPR/Cas9 to directly target the intron2 mutation site IVS2-654 in the globin gene. We observed different frequencies of double-strand breaks (DSBs) at IVS2-654 loci using TALENs and CRISPR/Cas9, and TALENs mediated a higher homologous gene targeting efficiency compared to CRISPR/Cas9 when combined with the piggyBac transposon donor. In addition, more obvious off-target events were observed for CRISPR/Cas9 compared to TALENs. Finally, TALENs-corrected iPSC clones were selected for erythroblast differentiation using the OP9 co-culture system and detected relatively higher transcription of HBB than the uncorrected cells. This comparison of using TALENs or CRISPR/Cas9 to correct specific HBB mutations in patient-derived iPSCs will guide future applications of TALENs- or CRISPR/Cas9-based gene therapies in monogenic diseases.


PROVIDER: S-EPMC4496796 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6850948 | BioStudies
2018-01-01 | S-EPMC6528953 | BioStudies
1000-01-01 | S-EPMC5442829 | BioStudies
2018-01-01 | S-EPMC6236008 | BioStudies
2015-01-01 | S-EPMC4628786 | BioStudies
2019-01-01 | S-EPMC6529457 | BioStudies
2015-01-01 | S-EPMC4351458 | BioStudies
2015-01-01 | S-EPMC4417674 | BioStudies
1000-01-01 | S-EPMC4974373 | BioStudies
2015-01-01 | S-EPMC4642230 | BioStudies